- tags:presbyopia
Pipeline
Lenz Therapeutics and Corxel release positive phase 3 presbyopia data from China
Statistically significant topline data supports LNZ100’s safety profile just days after the FDA accepts LENZ’s NDA for potential U.S. regulatory approval.
Pipeline
FDA accepts Lenz Therapeutics’ NDA for presbyopia eye drops
PDUFA target action date on LNZ100 (1.75% aceclidine) is set for August 2025
Products
FDA approves Bausch + Lomb's en Vista Envy IOL
Offering a continuous range of vision with excellent dysphotopsia tolerance, the lens will be initially available on a limited basis.
Products
Orasis secures financing to support US commercial launch of Qlosi
With $78 million in Series D financing, the preservative-free pilocarpine solution is one step closer to availability.
Products
J&J expands US rollout of TECNIS Odyssey IOL
Purely refractive presbyopia-correcting lens provides full visual range with minimal visual complaints and higher tolerance to residual refractive errors.
Pipeline
Ocuphire doses first patient in phase 3 presbyopia study on phentolamine solution
Already FDA approved as RYZUMVI for reversal of mydriasis, VEGA-3 topline data on POS 0.75% is expected by early 2025.
Pipeline
Lenz Therapeutics submits NDA for presbyopia eye drop
FDA has 60 days to review LNZ100 (1.75% aceclidine) as a pupil-selective and long-lasting therapeutic option.
Pipeline
Refractive tech startup TECLens gets J&J investment
Private medical device company’s corneal cross-linking technology operates as a non-invasive, in-office treatment for keratoconus and progressive pediatric myopia.
Events
Experts weigh in on key trends in anterior segment innovations
Ophthalmic leaders cover market opportunities, bridging the gap between physicians and industry, as well as premium patient outcomes for the future.
Products
Bausch + Lomb's enVista Envy IOL secures Canadian approval
Acceptance marks first global regulatory approval for the new lens; company notes FDA approval is pending.
Pipeline
LENZ Therapeutics reports positive phase 3 data for presbyopia eye drops
CLARITY 1 and 2 trials report statistically significant topline data for single-use, once-daily, and preservative-free LNZ100.Products
Johnson & Johnson unveils TECNIS Odyssey presbyopia-correcting IOL
Real-world data presented during ASCRS reports the IOL demonstrates a full range of continuous vision.
Business
Lenz Therapeutics merges with Graphite Bio
Combined company under LENZ is focusing on advancing two presbyopia therapeutic candidates.
Research
VTI reports data from Defocus Curve study with mature presbyopes
Promising results support use of NaturalVue Enhanced Multifocal contact lens design.
Products
Azalea Vision performs first on-eye test of smart contact lens
Lens has potential as a non-surgical solution to filter aberrated light and enhance QOL for presbyopia, keratoconus, and light-sensitive patients.
Products
Adaptive focus sunglasses feature dynamic lens for presbyopia
Deep Optics’ eyeglasses are marketed as the first and only adaptive reading sunglasses to combine multiple prescriptions in one.
Business
LENZ Therapeutics and Graphite Bio are merging to focus on presbyopia
The $225 million agreement will be used to advance the lead programs for 2 investigational eye drops.
Business
Ace Vision adds new CMO, medical advisory board members, and websites
Ace Vision adds new CMO, medical advisory board members, and websites
Products
FDA approves Orasis's QLOSI for presbyopia
The preservative-free, low-dose eye drop will be commercially available in 2024.
Research